“Structural Determination of Sacsin” – Dr. Walid Houry
We have carried out early in vitro characterizations of Sacsin, and we are working to obtain its three-dimensional (3D) structure using cryogenic electron microscopy.
Thursday, November 23, 2023

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a non-treatable neurodegenerative genetic disorder of early childhood and adulthood. When first reported in 1978, ARSACS was described as a unique form of ataxia, accompanied with motor speech anomalies, muscle wasting phenotypes, and peripheral nerve complications. ARSACS symptoms worsen in adulthood, with most individuals losing the ability to walk by the age of 50. Genetic studies have established that ARSACS is caused by mutations in Sacsin – a protein whose biology is poorly known. Current research suggests that Sacsin supports cytoskeletal and mitochondrial organization. To shed light on Sacsin function, one needs to study Sacsin structure in both native and mutated states. However, no published research has described the purification of Sacsin protein for in vitro and structural investigations. This technical gap in research is due to the large size of Sacsin (~520 kDa). Our laboratory has now solved this issue. We have carried out early in vitro characterizations of Sacsin, and we are working to obtain its three-dimensional (3D) structure using cryogenic electron microscopy. Our current focus is to increase the resolution of our 3D model and, subsequently, begin in silico drug screening.
Quick Reads
Nulla sed nibh eleifend orci finibus tempus. Mauris sit amet arcu placerat, molestie odio a, auctor nisi.

New Funding
“Dimethyl Fumarate Tested on the ARSACS Mouse Model” – Drs. Wolter & Wang
This project, led by Drs. Justin Wolter and Huaxia Wang, aims to test the therapeutic potential of dimethyl fumarate (DMF) in the ARSACS mouse model.

New Funding
“Modelling ARSACS in human in iPSC-derived cerebellar organoids ” – Dr. Esther Becker
This project aims to create three-dimensional disease models called ‘organoids’ using induced pluripotent stem cells (iPSCs) from ARSACS patients.